|
1
|
Zhu AX: Molecularly targeted therapy for
advanced hepatocellular carcinoma in 2012: Current status and
future perspectives. Semin Oncol. 39:493–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Psyrri A, Arkadopoulos N, Vassilakopoulou
M, Smyrniotis V and Dimitriadis G: Pathways and targets in
hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coulouarn C, Factor VM, Andersen JB,
Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver
cancer correlates with suppression of the hepatic phenotype and
gain of metastatic properties. Oncogene. 28:3526–3536. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
miR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin W, Zhao Y, Ji YJ, Tong LP, Liu Y, He
SX and Wang AQ: Serum/plasma microRNAs as biomarkers for
HBV-related hepatocellular carcinoma in China. Biomed Res Int.
2015:9651852015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang K, Jia Z, Zou J, Zhang A, Wang G, Hao
J, Wang Y, Yang S and Pu P: Analysis of hsa-miR-30a-5p expression
in human gliomas. Pathol Oncol Res. 19:405–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D,
Liu Z and Huang JA: Expression profile analysis of microRNAs and
downregulated miR-486-5p and miR-30a-5p in non-small cell lung
cancer. Oncol Rep. 34:1779–1786. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin L, Miller CT, Contreras JI, Prescott
MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, et
al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1),
on chromosome band 14q13 is amplified and overexpressed in
esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279.
2002.PubMed/NCBI
|
|
14
|
Zhao Y and Li Z: Interplay of estrogen
receptors and FOXA factors in the liver cancer. Mol Cell
Endocrinol. 418:334–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q,
Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth
of human hepatocellular carcinoma by targeting FOXA1. Oncotarget.
6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
França AV, Junior Elias J, Lima BL,
Martinelli AL and Carrilho FJ: Diagnosis, staging and treatment of
hepatocellular carcinoma. Braz J Med Biol Res. 37:1689–1705. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Visone R, Pallante P, Vecchione A,
Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V,
Borbone E, et al: Specific microRNAs are downregulated in human
thyroid anaplastic carcinomas. Oncogene. 26:7590–7595. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia Z, Wang K, Wang G, Zhang A and Pu P:
MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth
by targeting SEPT7. PLoS One. 8:e550082013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Tuteja G, Schug J and Kaestner KH:
Foxa1 and Foxa2 are essential for sexual dimorphism in liver
cancer. Cell. 148:72–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lupien M, Eeckhoute J, Meyer CA, Wang Q,
Zhang Y, Li W, Carroll JS, Liu XS and Brown M: FoxA1 translates
epigenetic signatures into enhancer-driven lineage-specific
transcription. Cell. 132:958–970. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang
X, Weng W, Pan Q, Yu Y, Sun F and Wang J: Tumor suppressor long
non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to
inhibit FoxA1 in liver cancer cells. Cell Signal. 26:2961–2968.
2014. View Article : Google Scholar : PubMed/NCBI
|
